
## Hua Jin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11342323/publications.pdf Version: 2024-02-01



ΗΠΑΤΙΝ

#	Article	IF	CITATIONS
1	The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education. Annals of Neurology, 1990, 27, 428-437.	5.3	897
2	Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain. JAMA - Journal of the American Medical Association, 2008, 299, 185-93.	7.4	316
3	Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research, 2004, 71, 195-212.	2.0	187
4	The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China. Schizophrenia Research, 2015, 169, 109-115.	2.0	176
5	A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. Schizophrenia Research, 2006, 86, 36-44.	2.0	174
6	Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Atypical Antipsychotics: An Analysis of 45 Published Cases. Annals of Clinical Psychiatry, 2002, 14, 59-64.	0.6	159
7	Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophrenia Research, 2008, 100, 70-85.	2.0	133
8	Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia. Archives of General Psychiatry, 2010, 67, 895.	12.3	124
9	Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry, 2002, 14, 59-64.	0.6	95
10	Depression and suicidality in HIV/AIDS in China. Journal of Affective Disorders, 2006, 94, 269-275.	4.1	93
11	Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings. Schizophrenia Research, 2013, 144, 37-42.	2.0	84
12	Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. Journal of NeuroVirology, 2008, 14, 536-549.	2.1	82
13	Successful aging in Shanghai, China: definition, distribution and related factors. International Psychogeriatrics, 2006, 18, 551.	1.0	81
14	Association of Posttraumatic Stress Disorder With Increased Prevalence of Metabolic Syndrome. Journal of Clinical Psychopharmacology, 2009, 29, 210-215.	1.4	57
15	Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophrenia Research, 2011, 125, 295-299.	2.0	53
16	Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. Aids, 2010, 24, 983-990.	2.2	52
17	Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PLoS ONE, 2016, 11, e0143490.	2.5	52
18	APOE Îμ4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. Aids, 2010, 24, 1471-1479.	2.2	49

Hua Jin

#	Article	IF	CITATIONS
19	Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40. Journal of Clinical Psychiatry, 2013, 74, 10-18.	2.2	46
20	Neurobehavioral effects of HIV-1 infection in China and the United States: A pilot study. Journal of the International Neuropsychological Society, 2007, 13, 781-90.	1.8	45
21	Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study. Neuroscience Letters, 2011, 503, 141-146.	2.1	34
22	Neuropsychological Performance in Mainland China: The Effect of Urban/Rural Residence and Self-Reported Daily Academic Skill Use. Journal of the International Neuropsychological Society, 2011, 17, 163-173.	1.8	28
23	Metabolic Syndrome: Relative Risk Associated with Post-Traumatic Stress Disorder (PTSD) Severity and Antipsychotic Medication Use. Psychosomatics, 2012, 53, 550-558.	2.5	26
24	Regional white matter abnormalities in drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings. Australian and New Zealand Journal of Psychiatry, 2015, 49, 246-254.	2.3	25
25	Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology, 2018, 235, 3545-3558.	3.1	25
26	What is the optimal neuropsychological test battery for schizophrenia in China?. Schizophrenia Research, 2019, 208, 317-323.	2.0	22
27	Cognitive deficits in subjects at risk for psychosis, first-episode and chronic schizophrenia patients. Psychiatry Research, 2019, 274, 235-242.	3.3	20
28	Use of Clinical Markers to Identify Metabolic Syndrome in Antipsychotic-Treated Patients. Journal of Clinical Psychiatry, 2010, 71, 1273-1278.	2.2	18
29	Absence of neurocognitive impairment in a large Chinese sample of HCV-infected injection drug users receiving methadone treatment. Drug and Alcohol Dependence, 2014, 137, 29-35.	3.2	16
30	Clinical Correlates of Insulin Resistance in Chronic Schizophrenia: Relationship to Negative Symptoms. Frontiers in Psychiatry, 2019, 10, 251.	2.6	13
31	The Influence of HLA on HIV-Associated Neurocognitive Impairment in Anhui, China. PLoS ONE, 2012, 7, e32303.	2.5	12
32	Psychiatric context of Human Immunodeficiency Virus infection among former plasma donors in rural China. Journal of Affective Disorders, 2011, 130, 421-428.	4.1	11
33	A novel biomarker of cardiometabolic pathology in schizophrenia?. Journal of Psychiatric Research, 2019, 117, 31-37.	3.1	10
34	Discontinuation of Quetiapine From an NIMH-Funded Trial Due to Serious Adverse Events. American Journal of Psychiatry, 2009, 166, 937-938.	7.2	8
35	Effects of transcranial direct current stimulation on cognition and symptoms in Chinese patients with schizophrenia✰. Psychiatry Research, 2020, 284, 112617.	3.3	8
36	Gene expression of methylation cycle and related genes in lymphocytes and brain of patients with schizophrenia and non-psychotic controls. Biomarkers in Neuropsychiatry, 2021, 5, 100038.	1.0	7

Hua Jin

#	Article	IF	CITATIONS
37	Decreasing risk of psychosis by sulforaphane study protocol for a randomized, doubleâ€blind, placeboâ€controlled, clinical multiâ€centre trial. Microbial Biotechnology, 2021, 15, 585-594.	1.7	6
38	Subtype associations with HIV-associated neurocognitive disorder in China. Journal of NeuroVirology, 2016, 22, 246-250.	2.1	5
39	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2095-2104.	2.2	3
40	Increased prevalence of metabolic syndrome in Veterans with PTSD untreated with antipsychotic medications. International Journal of Mental Health, 2023, 52, 45-60.	1.3	3
41	Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial. Schizophrenia Bulletin Open, 2022, 3, .	1.7	3
42	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophrenia Research, 2021, 230, 87-94.	2.0	2
43	OUP accepted manuscript. Schizophrenia Bulletin, 2022, , .	4.3	1